Financial Reports

RaySearch Laboratories AB (publ) Interim Report January 1 – March 31, 2013

JANUARY 1 – MARCH 31, 2013

  • Net sales for the period amounted to SEK 47.9 M (38.4)
  • Profit after tax totaled SEK 5.2 M (4.6) and earnings per share was SEK 0.15 (0.13)
  • Operating profit was SEK 8.1 M (6.7)
  • Cash flow amounted to SEK 0.6 M (10.9)
  • First orders for RayStation® from Spain and France
  • RayStation® 3.5 released


  • RaySearch licensed technology from GSI
  • Major treatment center in Maryland selected RayStation®

“Net sales increased by 25 percent during the first quarter thanks to increasing sales of RayStation® as well as increasing sales via partners,” says Johan Löf, President of RaySearch.

“The year has started well and RayStation® is evolving at a fast pace. While considerable work remains ahead for expanding our sales and service organization, interest in the system is rising continuously and we are involved in an increasing number of business discussions throughout the world. It is difficult to predict how rapidly the interest will translate into orders and deliveries, but we are looking forward to the rest of 2013 with confidence,” concludes Johan Löf.

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA Dosimetry, Varian and Accuray. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit

Johan Löf, President
Tel: +46 (0)8-545 061 30